A team led by scientists at Lawrence Berkeley National Laboratory reports that double strand breaks in DNA, occurring genome wide, drive neurodegeneration in a mouse model of Huntington's disease independently of the CAG repeat expansion that most current and experimental therapies target. The findings, published in Nature Communications on May 6, 2026 (first posted as a preprint on bioRxiv in May 2025), come from studies in male HdhQ150/150 mice, a genetic model engineered to carry the human Huntington's mutation. The mutant huntingtin protein was found to suppress a DNA repair process called non homologous end joining, allowing double strand breaks to accumulate across the genome; this is distinct from the site specific growth of the CAG repeat itself, which the researchers say is driven by a separate repair pathway called mismatch repair. The two forms of DNA damage occur together in the same brain cells but appear to act through different mechanisms.

Huntington's disease is a fatal, inherited condition in which a mutated gene carrying an expanded, repeating DNA sequence leads to progressive loss of neurons controlling movement, thinking and mood. Decades of drug development, including gene silencing, antisense oligonucleotide and CRISPR based approaches, have focused on lowering or blocking the mutant protein or halting the repeat expansion; none of these strategies has yet succeeded in reversing the disease in clinical trials, according to the researchers. In the new study, mice engineered so their CAG repeats could not expand somatically still developed DNA strand breaks and transcriptional problems in neurons, indicating the breaks alone can drive disease features even without repeat growth. Conversely, when the researchers suppressed the strand breaks in mice that were still expanding their CAG repeats, the study reports that neuronal toxicity was reversed.

To test whether blocking the breaks could help symptoms, the team treated HD model mice with a daily infusion of an investigational antioxidant compound called XJB-5-131, developed by a University of Pittsburgh chemist and designed to concentrate in neurons' mitochondria. According to the Berkeley Lab announcement, treated mice showed fewer double strand breaks, no measurable motor function deficits and reduced brain inflammation. Co-lead author Aris Polyzos, a biochemist at Berkeley Lab, said the effect occurred without altering the mutant gene or stopping the repeat expansion, the approaches that have driven most past and ongoing experimental treatments.

The authors and outside readers alike should treat the result as an early, single-model finding. It was conducted entirely in male mice of one genetic line, using DNA damage and motor measures as the outcomes; no human trial, human tissue confirmation, or safety and dosing data in people has been reported for the compound used. Researchers describe the DNA repair pathway as a new potential class of drug target for Huntington's, distinct from repeat lowering approaches, but caution that translating a mouse finding into a treatment for people typically takes years of further study, including toxicology, dosing and human trials that have not yet begun.